136 related articles for article (PubMed ID: 11565632)
1. D2 receptor occupancy under recommended and high doses of olanzapine.
Harvey EJ; Taylor DM; Flanagan RJ
J Psychopharmacol; 2001 Sep; 15(3):213-4. PubMed ID: 11565632
[No Abstract] [Full Text] [Related]
2. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients.
Nordström AL; Nyberg S; Olsson H; Farde L
Arch Gen Psychiatry; 1998 Mar; 55(3):283-4. PubMed ID: 9510228
[No Abstract] [Full Text] [Related]
3. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
[TBL] [Abstract][Full Text] [Related]
4. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ
J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054
[TBL] [Abstract][Full Text] [Related]
5. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.
Raedler TJ; Knable MB; Lafargue T; Urbina RA; Egan MF; Pickar D; Weinberger DR
Psychiatry Res; 1999 Apr; 90(2):81-90. PubMed ID: 10482380
[TBL] [Abstract][Full Text] [Related]
6. Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
Schmitt GJ; Meisenzahl EM; Dresel S; Tatsch K; Rossmüller B; Frodl T; Preuss UW; Hahn K; Möller HJ
J Psychopharmacol; 2002 Sep; 16(3):200-6. PubMed ID: 12236625
[TBL] [Abstract][Full Text] [Related]
7. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
[TBL] [Abstract][Full Text] [Related]
9. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S
Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964
[TBL] [Abstract][Full Text] [Related]
10. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
de Haan L; Lavalaye J; Linszen D; Dingemans PM; Booij J
Am J Psychiatry; 2000 Jun; 157(6):1019-20. PubMed ID: 10831489
[TBL] [Abstract][Full Text] [Related]
11. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
[TBL] [Abstract][Full Text] [Related]
12. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
13. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
Pilowsky LS; Busatto GF; Taylor M; Costa DC; Sharma T; Sigmundsson T; Ell PJ; Nohria V; Kerwin RW
Psychopharmacology (Berl); 1996 Mar; 124(1-2):148-53. PubMed ID: 8935810
[TBL] [Abstract][Full Text] [Related]
14. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.
Nyberg S; Farde L; Halldin C
Neuropsychopharmacology; 1997 Jan; 16(1):1-7. PubMed ID: 8981383
[TBL] [Abstract][Full Text] [Related]
15. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.
Fanous A; Lindenmayer JP
J Clin Psychopharmacol; 1999 Jun; 19(3):275-6. PubMed ID: 10350037
[No Abstract] [Full Text] [Related]
16. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
17. Acute dystonia caused by low dosage of olanzapine.
Alevizos B; Papageorgiou C; Christodoulou GN
J Neuropsychiatry Clin Neurosci; 2003; 15(2):241. PubMed ID: 12724469
[No Abstract] [Full Text] [Related]
18. Writer's cramp induced by olanzapine.
Vaamonde J; González JM; Hernádez A; Ibáñez R; Gudin MA; Del Real Francia MA
J Neurol; 2001 May; 248(5):422. PubMed ID: 11437166
[No Abstract] [Full Text] [Related]
19. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.
Mizrahi R; Rusjan P; Agid O; Graff A; Mamo DC; Zipursky RB; Kapur S
Am J Psychiatry; 2007 Apr; 164(4):630-7. PubMed ID: 17403977
[TBL] [Abstract][Full Text] [Related]
20. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]